A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial).

Liver Cirrhosis Clinical Trial

— COMBAT  

Official title:

A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial).

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05895136
• Other study ID #: COMBAT
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: March 2024
• Est. completion date: March 2025

Study information

• Verified date: February 2024
• Source: European Foundation for Study of Chronic Liver Failure
• Contact: Anna Bosch
• Phone: +34 93 227 14 03
• Email: anna.bosch[@]efclif.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to determine primarily whether a combinatorial therapy based on the administration of human albumin and enoxaparin is safe and effective in patients with decompensated cirrhosis discharged from the hospital. The main questions it aims to answer are:

• Is this combinatorial therapy safe and tolerable?

• Is this combinatorial therapy effective?

• does this combinatorial therapy cost more or less than standard medical therapy? Participants will attend to study visits in which several test will be performed to asses disease evolution while they are taking study medication.

Researchers will compare experimental group treated with combinatorial therapy plus standard treatment with control group treated with standard treatment to see if there are differences in the responses to the questions raised above.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 90
• Est. completion date: March 2025
• Est. primary completion date: March 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Age between 18 and 80 years.

• Patients with decompensated cirrhosis admitted to hospital due to AD according to the EASL-CLIF criteria (rapid onset of ascites, hepatic encephalopathy, portal hypertensive-related gastrointestinal bleeding, bacterial infection, or any combination of these).

• CLIF-C AD score >= 50 at admission or at any time during hospital stay.

• Recovery from AD and expected to be discharged within the next 48-72 hours.

Exclusion Criteria:

• Diagnosis of acute-on-chronic liver failure (ACLF) grade 2 or higher according to the EASL-CLIF criteria at admission or at any time during the index hospitalization

• Admission for planned diagnostic or therapeutic procedures

• Recent acute bleeding (unless the cause has been effectively treated and evidence of ongoing bleeding has not been identified for at least 5 days)

• Chronic bleeding requiring periodic blood transfusions

• Severe thrombocytopenia (=20x109/L)

• Ongoing chronic anticoagulation therapy or indication for starting anticoagulation due to hepatic and non-hepatic conditions

• Ongoing anti-platelets therapy.

• Active malignancy (except for hepatocellular carcinoma within the Milan criteria or non-melanocytic skin cancer)

• Antiviral treatment for hepatitis C, B and delta initiated in the last 6 months or planned to be initiated in the following 6 months

• Ongoing alcohol use disorder with an expected low adherence to protocol as judged by physician

• Previous liver transplantation

• Patients with TIPS or other surgical porto-caval shunts

• Chronic organic renal failure stage IV and V or estimated Glomerular Filtration Rate <20 ml/min according to the MDRD equations

• Chronic heart failure NYHA class III or IV

• Pulmonary disease GOLD III or IV

• Patients with a history of significant extrahepatic disease with life expectancy <6 months

• Severe psychiatric disorders

• Known allergy or intolerance to human albumin or enoxaparin

• Pregnancy and breast-feeding

• Expected low adherence to study protocol as judged by physician

• Refusal to participate (no signed informed consent)

• Patients who cannot provide prior informed consent and when there is documented evidence that the patient has no legal surrogate decision-maker and it appears unlikely that the patient will regain consciousness or sufficient ability to provide delayed informed consent.

Related Conditions & MeSH terms

• Fibrosis
• Liver Cirrhosis

Intervention

Drug:
• Human albumin
Human albumin solution is made from pooled human plasma. It is widely used as a plasma-expander in several disease conditions, such as liver cirrhosis and critically ill patients. ATC-Code: B05AA01
• Enoxaparin
Enoxaparin is a drug that belongs to the group of anticoagulants. It exerts its antithrombotic activity by binding to antithrombin III (AT III). ATC-Code: B01AB05
• Standard medical treatment
SMT will be considered non-study medication and is not specified in the protocol.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
European Foundation for Study of Chronic Liver Failure

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The percentage of subjects who experience at least 1 treatment-emergent AE (TEAE) or SAE.	A descriptive analysis will be performed for all safety parameters overall and by treatment arm at every study time-point. Categorical parameters will be presented by counts and percentages.; Continuous parameters will be summarized by means of the appropriate descriptive statistics (mean ± standard deviation or median and interquartile range). The main safety end-points will be descriptively compared between treatment arms.	from baseline to Day 90
Primary	The percentage of subjects who discontinue the study drug due to pulmonary edema and/or major bleeding according to the definition by Shulman et al	A descriptive analysis will be performed for all safety parameters overall and by treatment arm at every study time-point. Categorical parameters will be presented by counts and percentages.; Continuous parameters will be summarized by means of the appropriate descriptive statistics (mean ± standard deviation or median and interquartile range). The main safety end-points will be descriptively compared between treatment arms.	from baseline to Day 90
Secondary	90 and 180-days changes in prognostic scores of CLIF-Consortium Acute Decompensation score (CLIF-C AD) from baseline.	Lower scores of CLIF-C AD (<45) indicate a better prognostic than greater values (>50). In the statistical analysis Chi-Square test or Fisher exact test will be performed. Pairwise Log-rank tests will be used for statistical comparisons.	90 and 180-days from baseline
Secondary	90 and 180-days changes in prognostic scores of Mayo End stage Liver Disease (MELD) from baseline.	The MELD score ranges from six to 40 and is based on results from several lab tests. The higher the number, the more likely you are to receive a liver from a deceased donor when an organ becomes available.; Chi-Square test or Fisher exact test will be performed. Pairwise Log-rank tests will be used for statistical comparisons.	90 and 180-days from baseline
Secondary	90 and 180-days changes in prognostic scores of Mayo End stage Liver Disease - sodio (MELDNa) from baseline	The MELDNa score ranges from six to 40 and is based on results from several lab tests. The higher the number, the more likely you are to receive a liver from a deceased donor when an organ becomes available.; Chi-Square test or Fisher exact test will be performed. Pairwise Log-rank tests will be used for statistical comparisons.	90 and 180-days from baseline
Secondary	30 days, 90 and 180-days incidence of hospital readmission and ICU admission (causes and length of stay)	Chi-Square test or Fisher exact test will be performed. Pairwise Log-rank tests will be used for statistical comparisons.	30, 90 and 180-days
Secondary	90 and 180-days incidence of ACLF according to the EASL-CLIF criteria	Chi-Square test or Fisher exact test will be performed. Pairwise Log-rank tests will be used for statistical comparisons.	90 and 180-days from baseline
Secondary	90 and 180-days overall and transplant-free survival	Overall and transplant-free survival will be analyzed by estimating Kaplan-Meier survival curves for each treatment arm. Pairwise Log-rank tests will be used for statistical comparisons.	90 and 180-days from baseline
Secondary	90 and 180-days incidence and cumulative number of therapeutic paracenteses	Chi-Square test or Fisher exact test will be performed. Pairwise Log-rank tests will be used for statistical comparisons.	90 and 180-days from baseline
Secondary	90 and 180-days incidence of major complication of cirrhosis (grade 2-4 HE, portalhypertensive gastrointestinal bleedings, AKI, HRS-AKI, new-onset portal vein thrombosis)	Chi-Square test or Fisher exact test will be performed. Pairwise Log-rank tests will be used for statistical comparisons.	90 and 180-days from baseline
Secondary	90 and 180-days incidence of proven bacterial infection	Chi-Square test or Fisher exact test will be performed. Pairwise Log-rank tests will be used for statistical comparisons.	90 and 180-days from baseline
Secondary	90 and 180-days changes in organ function from baseline: liver function variables: grade of ascites	Grade of ascites according to the criteria of the International Club of Ascites.; Student t-test or analysis of variance will be used to compare normally distributed variable or non-parametric methods if the assumptions of normality are not met. Pairwise Log-rank tests will be used for statistical comparisons.	90 and 180-days from baseline
Secondary	90 and 180-days changes in organ function from baseline: liver function variables: grade of hepatic encephalopathy (West Haven)	Grade of hepatic encephalopathy using the West Haven (score range 0, normal to 4, coma).; Student t-test or analysis of variance will be used to compare normally distributed variable or non-parametric methods if the assumptions of normality are not met. Pairwise Log-rank tests will be used for statistical comparisons.	90 and 180-days from baseline
Secondary	90 and 180-days changes in organ function from baseline: liver function variables: grade of hepatic encephalopathy (ANT)	Animal Naming Test (ANT): range from >15, normal to <10; Student t-test or analysis of variance will be used to compare normally distributed variable or non-parametric methods if the assumptions of normality are not met. Pairwise Log-rank tests will be used for statistical comparisons.	90 and 180-days from baseline
Secondary	90 and 180-days changes in organ function from baseline: liver function variables: bilirrubin	Bilirubin in mg/dL. Ranges according reference ranges of each study site.; Student t-test or analysis of variance will be used to compare normally distributed variable or non-parametric methods if the assumptions of normality are not met. Pairwise Log-rank tests will be used for statistical comparisons.	90 and 180-days from baseline
Secondary	90 and 180-days changes in organ function from baseline: liver function variables: albumin serum levels	Albumin serum levels in g/dL. Ranges according reference ranges of each study site.; Student t-test or analysis of variance will be used to compare normally distributed variable or non-parametric methods if the assumptions of normality are not met. Pairwise Log-rank tests will be used for statistical comparisons.	90 and 180-days from baseline
Secondary	90 and 180-days changes in organ function from baseline: renal function variables: BUN	BUN in mg/dL. Ranges according reference ranges of each study site.; Student t-test or analysis of variance will be used to compare normally distributed variable or non-parametric methods if the assumptions of normality are not met. Pairwise Log-rank tests will be used for statistical comparisons.	90 and 180-days from baseline
Secondary	90 and 180-days changes in organ function from baseline: renal function variables: serum creatinine	Serum creatinine in mg/dL. Ranges according reference ranges of each study site.; Student t-test or analysis of variance will be used to compare normally distributed variable or non-parametric methods if the assumptions of normality are not met. Pairwise Log-rank tests will be used for statistical comparisons.	90 and 180-days from baseline
Secondary	90 and 180-days changes in organ function from baseline: renal function variables: electrolites	Electrolytes: Na, K, Ca (mmol/L). Ranges according reference ranges of each study site.; Student t-test or analysis of variance will be used to compare normally distributed variable or non-parametric methods if the assumptions of normality are not met. Pairwise Log-rank tests will be used for statistical comparisons.	90 and 180-days from baseline
Secondary	90 and 180-days changes in organ function from baseline: renal function variables: GFR	Glomerula Filtration Ratio (GFR) will be estimated by the Modification of Diet in Renal Disease (MDRD) equations.; Student t-test or analysis of variance will be used to compare normally distributed variable or non-parametric methods if the assumptions of normality are not met. Pairwise Log-rank tests will be used for statistical comparisons.	90 and 180-days from baseline
Secondary	90 and 180-days changes in organ function from baseline: lung function variables: respiratory rate	Respiratory rate in breaths per minute. Ranges according reference ranges of each study site.; Student t-test or analysis of variance will be used to compare normally distributed variable or non-parametric methods if the assumptions of normality are not met. Pairwise Log-rank tests will be used for statistical comparisons.	90 and 180-days from baseline
Secondary	90 and 180-days changes in organ function from baseline: lung function variables: FIO2	Fraction of inspired oxygen (FIO2) in percentage (%). Ranges according reference ranges of each study site.; Student t-test or analysis of variance will be used to compare normally distributed variable or non-parametric methods if the assumptions of normality are not met. Pairwise Log-rank tests will be used for statistical comparisons.	90 and 180-days from baseline
Secondary	90 and 180-days changes in organ function from baseline: lung function variables: pulse oxymetric saturation	Pulse oxymetric saturation in percentage (%). Ranges according reference ranges of each study site.; Student t-test or analysis of variance will be used to compare normally distributed variable or non-parametric methods if the assumptions of normality are not met. Pairwise Log-rank tests will be used for statistical comparisons.	90 and 180-days from baseline
Secondary	90 and 180-days changes in organ function from baseline: coagulative variables: INR	International Normalized Ratio (INR). Ranges according reference ranges of each study site.; Student t-test or analysis of variance will be used to compare normally distributed variable or non-parametric methods if the assumptions of normality are not met. Pairwise Log-rank tests will be used for statistical comparisons.	90 and 180-days from baseline
Secondary	90 and 180-days changes in organ function from baseline: coagulative variables: aPTT	Activated partial thromboplastin time (aPTT) in seconds. Ranges according reference ranges of each study site.; Student t-test or analysis of variance will be used to compare normally distributed variable or non-parametric methods if the assumptions of normality are not met. Pairwise Log-rank tests will be used for statistical comparisons.	90 and 180-days from baseline
Secondary	90 and 180-days changes in organ function from baseline: coagulative variables: fibrinogen	Fibrinogen in mg/dL. Ranges according reference ranges of each study site.; Student t-test or analysis of variance will be used to compare normally distributed variable or non-parametric methods if the assumptions of normality are not met. Pairwise Log-rank tests will be used for statistical comparisons.	90 and 180-days from baseline
Secondary	90 and 180-days changes in organ function from baseline: coagulative variables: Platelet count	Platelet count in platelets per microliter. Ranges according reference ranges of each study site.; Student t-test or analysis of variance will be used to compare normally distributed variable or non-parametric methods if the assumptions of normality are not met. Pairwise Log-rank tests will be used for statistical comparisons.	90 and 180-days from baseline
Secondary	90 and 180-days changes in organ function from baseline: hemodynamic variables: arterial pressure	Systolic, diastolic and mean arterial pressure in mmHg. Ranges according reference ranges of each study site.; Student t-test or analysis of variance will be used to compare normally distributed variable or non-parametric methods if the assumptions of normality are not met. Pairwise Log-rank tests will be used for statistical comparisons.	90 and 180-days from baseline
Secondary	90 and 180-days changes in organ function from baseline: hemodynamic variables: heart rate.	Heart rate in beats per minute. Ranges according reference ranges of each study site.; Student t-test or analysis of variance will be used to compare normally distributed variable or non-parametric methods if the assumptions of normality are not met. Pairwise Log-rank tests will be used for statistical comparisons.	90 and 180-days from baseline
Secondary	90 and 180-days changes in frailty (Liver Frailty Index, LFI)	LFI score of = 3.2 indicates a patient is robust, 3.3-4.4 pre frail and = 4.5 frail.; Student t-test or analysis of variance will be used to compare normally distributed variable or non-parametric methods if the assumptions of normality are not met. Pairwise Log-rank tests will be used for statistical comparisons.	90 and 180-days from baseline
Secondary	90 and 180-days changes in quality of life measure through European Quality of Life Five Dimension Five Levels (EQ-5D-5L)	EQ-5D-5L has a score from 5 (no problems) to 25 (extreme problems on all dimensions evaluated).; Student t-test or analysis of variance will be used to compare normally distributed variable or non-parametric methods if the assumptions of normality are not met. Pairwise Log-rank tests will be used for statistical comparisons.	90 and 180-days from baseline
Secondary	90 and 180-days changes in quality of life measure through Visual Analog Scale (VAS)	VAS has a score from 0 (worst health patient can imagine) to 100 (best health patient can imagine); Student t-test or analysis of variance will be used to compare normally distributed variable or non-parametric methods if the assumptions of normality are not met. Pairwise Log-rank tests will be used for statistical comparisons.	90 and 180-days from baseline
Secondary	Total hospital costs during the 6-month period	To estimate the 90-days costs of an acute decompensation of cirrhosis for both arms in the trial; In-hospital resource utilization will be described based on diagnosis and procedural codes and length of stay. Hospital costs will be assigned based on the primary indication for hospitalization and procedures performed during the hospitalization and the Severity-Diagnosis Related Groups. Costs will be then assigned based on the latest mean cost available.; Costs will be calculated in euros by treatment arm.; Student t-test or analysis of variance will be used to compare normally distributed variable or non-parametric methods if the assumptions of normality are not met. Pairwise Log-rank tests will be used for statistical comparisons.	180-days from baseline
Secondary	Total hospital costs predictors during the 6-month period	To identify cost predictors (patients characteristics that are present before the treatment is initiated) and; In-hospital resource utilization will be described based on diagnosis and procedural codes and length of stay. Hospital costs will be assigned based on the primary indication for hospitalization and procedures performed during the hospitalization and the Severity-Diagnosis Related Groups. Costs will be then assigned based on the latest mean cost available.; Costs will be calculated in euros by treatment arm.; Student t-test or analysis of variance will be used to compare normally distributed variable or non-parametric methods if the assumptions of normality are not met. Pairwise Log-rank tests will be used for statistical comparisons.	180-days from baseline
Secondary	Total hospital costs drivers during the 6-month period cost drivers	Cost drivers (response to treatment, randomization arm, other treatments).; In-hospital resource utilization will be described based on diagnosis and procedural codes and length of stay. Hospital costs will be assigned based on the primary indication for hospitalization and procedures performed during the hospitalization and the Severity-Diagnosis Related Groups. Costs will be then assigned based on the latest mean cost available.; Costs will be calculated in euros by treatment arm.; Student t-test or analysis of variance will be used to compare normally distributed variable or non-parametric methods if the assumptions of normality are not met. Pairwise Log-rank tests will be used for statistical comparisons.	180-days from baseline